BioNTech, a COVID-19 vaccine maker, has held confidential talks with potential buyers about the German sites it plans to close, according to the Handelsblatt newspaper.
The German company had announced in May that it would close three sites in Germany – Idar-Oberstein, Marburg, and Tuebingen – by the end of 2027, and also end operations in Singapore by the first quarter of next year, affecting up to 1,860 jobs.
BioNTech’s Berlin-based subsidiary JPT Peptides is also being put up for sale. The maker of peptides used in immunology and drug discovery is no longer profitable, and BioNTech plans to close it by the end of this year.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
